The availability of a minimally invasive patient simple, capable of providing tumor information, represents a valuable clinical tool. The liquid biopsy has the potential to achieve this need. Circulating cell free DNA (ccfDNA), other circulating nucleic acids such as microRNA and circulating tumor cells (CTCs), can be obtained from a peripheral blood sample. Liquid biopsy has been particularly studied in solid tumors, specially of the epitelial origin, such as a pancreatic carcinoma and advanced breast cancer. It has been considerably less applied to the study of non-solid tumors. It represents an important source for diagnosis, prognosis and predictive information. Also it is suitable to evaluate response to therapy and drugs pharmacokinetics. It provides a unique opportunity to evaluate the disease evolution in serial blood samples collection, otherwise difficult to obtain. Liquid biopsy can be rehearsed using different circulating biological fluids such as whole blood, serum, plasma and lymph, as well as, non-circulating fluids such as urine, feces, saliva, bile and accumulated pathological fluids such as ascites. This review summarizes the current status of circulating material analysis in non-solid tunors. It is specially focused on Hodgkin Lymphoma and among Non-Hodgkin Lymphoma, it refers particularly to Diffuse Large B cell Lymphoma, the most common aggressive Non-Hodgkin Lymphoma derived from germinal center B-cells in adults. It further discusses the benefit of liquid biopsy in oncohemtaological diseases and potential clinical applications.
Ashworth, T.R. (1869) A Case of Cancer in Which Cells Similar to Those in the Tumours Were Seen in the Blood after Death. The Medical Journal of Australia, 14, 146-147.
Mandel, P. and Métais, P. (1948) Les acides nucléiques du plasma sanguin chez l’Homme. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, 142, 241-243.
Engell, H.C. (1955) Cancer Cells in the Circulating Blood: A Clinical Study on the Occurrence of Cancer Cells in the Peripheral Blood an in Venous Blood Draining the Tumor Area at Operation. Acta chirurgica Scandinavica Supplementum, 201, 1-70.
Christopherson, W. (1965) Cancer Cells in the Peripheral Blood: A Second Look. Acta Cytologica, 9, 169-174.
Goessl, C., Heicappell, R., Münker, R., Anker, P., Stroun, M., Krause, H., Müller, M. and Miller, K. (1998) Microsatellite Analysis of Plasma DNA from Patients with Clear Cell Renal Carcinoma. Cancer Research, 58, 4728-4732.
Nawroz, H., Koch, W., Anker, P., Stroun, M. and Sidransky, D. (1996) Microsatellite Alterations in Serum DNA of Head and Neck Cancer Patients. Nature Medicine, 2, 1035-1037. https://doi.org/10.1038/nm0996-1035
Chen, X.Q., Stroun, M., Magnenat, J.L., Nicod, L.P., Kurt, A.M., Lyautey, J., Lederrey, C. and Anker, P. (1996) Microsatellite Alterations in Plasma DNA of Small Cell Lung Cancer Patients. Nature Medicine, 2, 1033-1035. https://doi.org/10.1038/nm0996-1033
Ranuncolo, S.M. (2016) Towards the Dreamed Biomarkers? Journal of Molecular Biomarkers & Diagnosis, S2, e002.
Alix-Panabières, C. and Pantel, K. (2013) Circulating Tumor Cells: Liquid Biopsy of Cancer. Clinical Chemistry, 59, 110-118.
De Mattos-Arruda, L., Cortes, J., Santarpia, I., Vivancos, A., Tabernero, J., Reis, J.S., et al. (2013) Circulating Tumour Cells and Cell-Free DNA as Tools for Managing Breast Cancer. Nature Reviews Clinical Oncology, 10, 377-389. https://doi.org/10.1038/nrclinonc.2013.80
Crowley, E., Di Nicolantonio, F., Loupakis, F. and Bardelli, A. (2013) Liquid Biopsy: Monitoring Cancer Genetics in the Blood. Nature Reviews Clinical Oncology, 10, 472-484. https://doi.org/10.1038/nrclinonc.2013.110
Scher, H.L., Moris, M.J., Larson, S. and Heller, G. (2013) Validation and Clinical Utility of Prostate Cancer Biomarkers. Nature Reviews Clinical Oncology, 10, 225-234. https://doi.org/10.1038/nrclinonc.2013.30
Woodcock, J. and Woosley, R. (2008) The FDA Critical Pathway Initiative and Its Influence on New Drug Development. Annu. Rev. Med., 59, 1-12. https://www.c-path.org/pdf/FDAcriticalpathinitiativeinfluenceonnewdrugdevelopmentWoodcockWoosley.pdf
Hayes, D.F., Allen, J., Compton, C., Gustavsen, G., Leonard, D.G., McCormack, R., et al. (2013) Breaking a Vicious Cycle. Science Translational Medicine, 5, 196cm6. https://doi.org/10.1126/scitranslmed.3005950
Center for Drug Evaluation and Research (CDER), Food & Drug Administration, United States Department of Health and Human Services (2011) Guidance for Industry: E16 Biomarkers Related to Drugs or Biotechnology Product Development: Context, Structure and Format of Quantification Submissions.
Michael, C. and Ball, J. (2010) Institute of Medicine (U.S.) Committee on Qualifications of Biomarkers and Surrogate Endpoints in Chronic Disease. Evaluation of Biomarkers and Surrogate Endpointsin Chronic Disease. National Academic Press, Washington DC, 314.
Parkinson, D.R., Dracopoli, N., Petty, B.G., Compton, C., Cristofanilli, M., Deisseroth, A., et al. (2012) Considerations in the Development of Cirsulting Tumor Cell Technology for Clinical Use. Journal of Translational Medicine, 10, 138. https://doi.org/10.1186/1479-5876-10-138
Karabacak, N.M., Spuhler, P.S., Fachin, F., Lim, E.J., Pai, V., Ozkumur, E., Martel, J.M., Kojic, N., Smith, K., Chen, P., Yang, J., Hwang, H., Morgan, B., Trautwein, J., Barber, T.A., Stott, S.L., Maheswaran, S., Kapur, R., Haber, D.A. and Toner, M. (2014) Microfluidic, Marker-Free Isolation of Circulating Tumor Cells from Blood Samples. Nature Protocols, 9, 694-710. https://doi.org/10.1038/nprot.2014.044
Yap, T.A., Lorente, D., Omlin, A., Olmos, D. and de Bono, J.S. (2007) Circulating Tumor Cells: A Multifunctional Biomarker. Clinical Cancer Research, 20, 2553-2568. https://doi.org/10.1158/1078-0432.CCR-13-2664
Nagrath, S., Sequist, L.V., Maheswaran, S., Bell, D.W., Irimia, D., Ulkus, L., Smith, M.R., Kwak, E.L., Digumarthy, S., Muzikansky, A., Ryan, P., Bails, U.J., Tompkins, R.G., Haber, D.A. and Toner, M. (2007) Isolation of Rare Circulating Tumour Cells in Cancer Patients by Microchip Technology. Nature, 450, 1235-1239. https://doi.org/10.1038/nature06385
Satelli, A., Mitra, A., Cultrera, J.J., Davarie, M., et al. (2014) Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Research, 74, 1645-1650. https://doi.org/10.1158/0008-5472.CAN-13-1739
Fleischhacker, M. and Schmidt, B. (2007) Circulating Nucleic Acids (CNAs) and Cancer—A Survey. Biochimica et Biophysica Acta, 1775, 181-232.
Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C. and Beljansky, M. (1989) Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients. Oncology, 46, 318-322. https://doi.org/10.1159/000226740
Thierry, A.R., Messaoudi, E.I., Gahan, P.B., Anker, P. and Stroun, M. (2016) Origins, Structures and Functions of Circulating DNA in Oncology. Cancer and Metastasis Reviews, 35, 347-376. https://doi.org/10.1007/s10555-016-9629-x
Gahan, P.B. and Stroun, M. (2010) The Virtosome—A Novel Cytosolic Informative Entity and Intercellular Messenger. Cell Biochemistry and Function, 28, 529-538. https://doi.org/10.1002/cbf.1690
Mouliere, F. and Thierry, A.R. (2012) The Importance of Examining the Proportion of Circulating DNA Originating from Tumor, Microenvironment and Normal Cells in Colorectal Cancer Patients. Expert Opinion on Biological Therapy, 12, S209-S215. https://doi.org/10.1517/14712598.2012.688023
Rykova, E.Y., Morozkin, E.S., Ponomaryova, A.A., Loseva, E.M., Zaporozhchenko, I.A., Cherdyntseva, N.V. and Laktionov, P.P. (2012) Cell-Free and Cell-Bound Circulating Nucleic Acid Complexes: Mechanisms of Generation, Concentration and Content. Expert Opinion on Biological Therapy, 12, S141-S153. https://doi.org/10.1517/14712598.2012.673577
Laktionov, P.P., Tamkovich, S.N., Rykova, E.Y., Bryzgunova, O.E., Starikov, A.V., Kuznetsova, N.P. and Vlassov, V.V. (2004) Cell-Surface-Bound Nucleic Acids: Free and Cell-Surface-Bound Nucleic Acids in Blood of Healthy Donors and Breast Cancer Patients. Annals of the New York Academy of Sciences, 1022, 221-227. https://doi.org/10.1196/annals.1318.034
Fan, H.C., Blumenfeld, Y.J., Chitkara, U., Hudgins, L. and Quake, S.R. (2008) Noninvasive Diagnosis of Fetal Aneuploidy by Shotgun Sequencing DNA from Maternal Blood. Proceedings of the National Academy of Sciences of the United States of America, 105, 16266-16271. https://doi.org/10.1073/pnas.0808319105
Lo, Y.M.D., Chan, K.C.A., Sun, H., Chen, E.Z., Jiang, P., Lun, F.M.F., Zheng, Y.W., Leung, T.Y., Lau, T.K., Cantor, C.R., et al. (2010) Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus. Science Translational Medicine, 2, 61ra91. https://doi.org/10.1126/scitranslmed.3001720
Holdenrieder, S., Stieber, P., Chan, L.Y.S., Geiger, S., Kremer, A., Nagel, D. and Lo, Y.M.D. (2005) Cell-Free DNA in Serum and Plasma: Comparison of ELISA and Quantitative PCR. Clinical Chemistry, 51, 1544-1546. https://doi.org/10.1373/clinchem.2005.049320
Wimberger, P., Roth, C., Pantel, K., Kasimir-Bauer, S., Kimmig, R. and Schwarzenbach, H. (2010) Impact of Platinum-Based Chemotherapy on Circulating Nucleic Acid Levels, Protease Activities in Blood and Disseminated Tumor Cells in Bone Marrow of Ovarian Cancer Patients. International Journal of Cancer, 128, 2572-2580. https://doi.org/10.1002/ijc.25602
Snyder, M.W., Kircher, M., Hill, A.J., Daza, R.M. and Schendure, J. (2016) Cell-Free DNA Comprises an in Vivo Nucleosome Footprint That Informs Its Tissues-ofOrigin. Cell, 164, 57-68. https://doi.org/10.1016/j.cell.2015.11.050
Bidard, F.C., Weigelr, B. and Reis-Filho, J.S. (2013) Going with the Flow: From Circulating Tumor Cells to DNA. Science Translational Medicine, 5, 207ps14. https://doi.org/10.1126/scitranslmed.3006305
Chevillet, J.R., Kang, Q., Ruf, I.K., Briggs, H.A., Vojtech, L.N., Hughes, S.M. and Tewari, M. (2014) Quantitative and Stoichiometric Analysis of the microRNA Content of Exosomes. Proceedings of the National Academy of Sciences of the United States of America, 111, 14888-14893. https://doi.org/10.1073/pnas.1408301111
De Jong, O.G., Van Balkom, B.W.M., Schiffelers, R.M., Bouten, C.V.C. and Verhaar, M.C. (2014) Extracellular Vesicles: Potential Roles in Regenerative Medicine. Frontiers in Immunology, 5, 608. https://doi.org/10.3389/fimmu.2014.00608
Tetta, C., Ghigo, E., Silengo, L., Deregibus, M.C. and Camussi, G. (2013) Extracellular Vesicles as an Emerging Mechanism of Cell-to-Cell Communication. Endocrine, 44, 11-19. https://doi.org/10.1007/s12020-012-9839-0
Thakur, B.K., Zhang, H., Becker, A., Matei, I., Huang, Y., Costa-Silva, B.K. and Lyden, D. (2014) Double-Stranded DNA in Exosomes: A Novel Biomarker in Cancer Detection. Cell Research, 24, 766-769. https://doi.org/10.1038/cr.2014.44
Hohaus, S., Giachelia, M., Massini, G., Mansueto, G., Vannata, B., Bozzoli, V., Criscuolo, M., D’Alò, F., Martini, M., Larocca, L.M., Voso, M.T. and Leone, G. (2009) Cell-Free Circulating DNA in Hodgkin’s and Non-Hodgkin’s Lymphomas. Annals of Oncology, 20, 1408-1413. https://doi.org/10.1093/annonc/mdp006
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma. The New England Journal of Medicine, 329, 987-994. https://doi.org/10.1056/NEJM199309303291402
Basso, K. and Dalla-Favera, R. (2011) Germinal Centres and B Cell Lymphomagenesis. Nature Reviews Inmunology, 15, 172-184. https://doi.org/10.1038/nri3814
Camus, V., Sarafan-Vasseur, N., Bohers, E., Dubois, S., Mareschal, S., Bertrand, P., Viailly, P.J., Ruminy, P., Maingonnat, C., Lemasie, E., Stamatoullas, A., Picquenot, J.M., Cornic, M., Beaussire, L., Bastard, Ch., Frebourg, T., Tilly, H. and Jardin, F. (2016) Digital PCR for Quantification of Recurrent and Potentially Actionable Somatic Mutations in Cirsulating Free DNA from Patients with Diffuse Large B-Cell Lymphoma. Leukemia & Lymphoma, 57, 2171-2179. https://doi.org/10.3109/10428194.2016.1139703
Garcia, V., Garcia, J.M., Silva, J., Martin, P., Pena, C., Dominguez, G., Diaz, R., Herrera, M., Maximiano, C., Sabin, P., Rueda, A., Cruz, M.A., Rodriguez, J., Canales, M.A., Bonilla, F. and Provencio, M. (2009) Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival Implications. PLoS ONE, 4, e8173. https://doi.org/10.1371/journal.pone.0008173
Roscheweski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E.S., Staudt, L.M., Lai, C., Steinberg, S.M., Chen, C.C., Zheng, J., Willis, T.D., Faham, M. and Wilson, W.H. (2013) Circulating Tumour DNA and CT Monitoring in Patients with Untreated Diffuse Large B-Cell Lymphoma: A Correlative Biomarker Study. The Lancet Oncology, 16, 541-549. https://doi.org/10.1016/S1470-2045(15)70106-3
Colocci, N., Glantz, M. and Recht, L. (2004) Prevention and Treatment of Central Nervous System Involvement by Non-Hodgkin’s Lymphoma: A Review of the Literature. Seminars in Neurology, 24, 395-404. https://doi.org/10.1055/s-2004-861534
Sancho, J.M., Morgades, M., Alonso, N., Deben, G., Fernández de Sevilla, A., Vazquez, L., et al., on Behalf of Investigators of QUIT Study (PETHEMA GELTAMO and GOTEL Groups) (2008) Prospective Study on the Practice of Central Nervous System Prophylaxis and Treatment in Non-Hodgkin’s Lymphoma in Spain. Medicina Clínica (Barc), 131, 441-446. https://doi.org/10.1157/13126952
Feugier, P., Virion, J.M., Tilly, H., Haioun, C., Marit, G., Macro, M., et al. (2004) Incidence and Risk Factors for Central Nervous System Occurrence in Elderly Patients with Diffuse Large-B-Cell Lymphoma: Influence of Rituximab. Annals of Oncology, 15, 129-133. https://doi.org/10.1093/annonc/mdh013
Boehme, V., Schmitz, N., Zeynalova, S., Loeffler, M. and Pfreundschuh, M. (2009) CNS Events in Elderly Patients with Aggressive Lymphoma Treated with Modern Chemotherapy (CHOP-14) with or without Rituximab: An Analysis of Patients Treated in the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 113, 3896-3902. https://doi.org/10.1182/blood-2008-10-182253
Villa, D., Connors, J.M., Shenkier, T.N., Gascoyne, R.D., Sehn, L.H. and Savage, K.J. (2010) Incidence and Risk Factors for Central Nervous System Relapse in Patients with Diffuse Large B-Cell Lymphoma: The Impact of the Addition of Rituximab to CHOP Chemotherapy. Annals of Oncology, 21, 1046-1052. https://doi.org/10.1093/annonc/mdp432
Lemma, S.A., Pasanen, A.K., Haapasaari, K.M., Sippola, A., Sormunen, R., Soini, Y., Jantunen, E., Koivunen, P., Salokorpi, N., Bloiqu, R., Turpeenniemi-Hujanen, T. and Kuittinen, O. (2016) Similar Chemokine Receptor Profiles in Lymphomas with Central Nervous System Involvement—Possible Biomarkers for Patient Selection for Central Nervous System Prophylaxis, a Retrospective Study. European Journal of Haematology, 96, 492-501. https://doi.org/10.1111/ejh.12626
Purhonen, A.K., Juutilainen, A., Vanska, M., Lehtikangas, M., Lakkisto, P., Hamalainen, S., Koivula, I., Jantunen, E. and Pulkki, K. (2015) Human Plasma Cell-Free DNA as a Predictor of Infectious Complications of Neutropenic Fever in Hematological Patients. Infectious Diseases, 47, 255-259. https://doi.org/10.3109/00365548.2014.985711
Machado, A.S., Da Silva, R., Maghalares, M.C., et al. (2010) Ciculating Cell-Free and Epstein-Barr Virus DNA in Paediatric B-Non-Hodgkin Lymphomas. Leukemia & Lymphoma, 51, 1020-1027. https://doi.org/10.3109/10428191003746331
Mussolin, L., Pillon, M., d’Amore, E.S., et al. (2011) Minimal Disseminated Disease in High-Risk Burkitt’s Lymphoma Identifies Patients with Different Prognosis. Journal of Clinical Oncology, 29, 1779-1784. https://doi.org/10.1200/JCO.2010.32.8161
Mussolin, L., Bonvini, P., ALi-Tahar, K., et al. (2009) Kinetics of Humoral Response to ALK and Its Relationship with Minimal Residual Disease in Paediatric ALCL. Leukemia, 23, 400-402. https://doi.org/10.1038/leu.2008.184
Ali-Tahar, K., Damm-Welk, C., Burkhardt, B., et al. (2010) Correlation of the Autoantibody Response to the ALK Oncoantigen in Peditaric Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma with Tumor Dissemination and Relapse Risk. Blood, 115, 3314-3319. https://doi.org/10.1182/blood-2009-11-251892
Mussolin, L., Pillon, M., d’Amore, E.S., et al. (2005) Prevalence and Clinical Implications of Bone Marrow Involvement in Peditaric Anaplastic Large Cell Lymphoma. Leukemia, 19, 1643-1647. https://doi.org/10.1038/sj.leu.2403888
Mussolin, L., Burnelli, R., Pillon, M., Carraro, E., Farruggia, P., Todesco, A., Muscarin, M. and Rosolen, A. (2013) Plasma Cell-Free DNA in Paediatric Lymphomas. Journal of Cancer, 4, 323-329. https://doi.org/10.7150/jca.6226
Mouliere, F., El Messaoudi, S., Pang, D., Dritschilo, A. and Thierry, A.R. (2014) Multi-Marker Analysis of Circulating Cell-Free DNA toward Personalized Medicine for Colorectal Cancer. Molecular Oncology, 8, 927-941. https://doi.org/10.1016/j.molonc.2014.02.005
Kuppers, R., Klein, U., Hansmann, M.L. and Rajewsky, K. (1999) Cellular Origin of Human B-Cell Lymphomas. The New England Journal of Medicine, 341, 1520-1529. https://doi.org/10.1056/NEJM199911113412007
Stevenson, F.K., Sahota, S.S., Ottensmeier, C.H., Zhu, D., Forconi, F. and Hamblin, T.J. (2001) The Occurrence and Significance of V Gene Mutations in B Cell-Derived Human Malignancy. Advances in Cancer Research, 83, 81-116.
Kutz, D.M. (2015) Noninvasive Monitoring of DLBCL by Immunoglobulin HighThroughput Sequencing. Blood, 125, 3679-3687. https://doi.org/10.1182/blood-2015-03-635169
Rossi, D., Diop, F., Spaccarotella, E., Monti, S., Zanni, M., Rasi, S., Deambrogi, C., Spina, V., Bruscaggin, A., Favini, Ch., Serra, R., Rampni, A., Baldorini, R., Foa, R. and Gaidano, G. (2017) Diffuse Large B-Cell Lymphoma Genotyping on the Liquid Biopsy. Blood, published online. https://doi.org/10.1182/blood-2016-05-719641
Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson Jr., J., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.D., Wamke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O. and Staudt, L.M. (2000) Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. Nature, 403, 503-511. https://doi.org/10.1038/35000501
Bohers, E., Vially, P.J., Dubois, S., Bertrand, P., Maingonnat, C., Mareschal, S., Ruminy, P., Picquenot, J.M., Bastard, Ch., Desmots, F., Fest, T., Leroy, K., Tilly, H. and Jardin, F. (2015) Somatic Mutations of Cell-Free Circulating DNA Detected by Next-Generation Sequencing Reflect the Genetic Changes in Both Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphomas at the Time of Diagnosis. Haematologica, 100, e280-e284. https://doi.org/10.3324/haematol.2015.123612
Armand, P., Oki, Y., Neuberg, D.S., et al. (2013) Detection of Circulating Tumour DNA in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma. British Journal of Haematology, 163, 123-126. https://doi.org/10.1111/bjh.12439
Faham, M., Zheng, J., Moorhead, M., et al. (2012) Deep-Sequencing Approach for Minimal Residual Disease Detection in Acuate Lymphoblastic Leukemia. Blood, 120, 5173-5180. https://doi.org/10.1182/blood-2012-07-444042
Logan, A.C., Zhang, B., Narasimhan, B., et al. (2013) Minimal Residual Disease Quantification Using Consensus Primers and High-Throughput IGH Sequencing Predicts Post-Transplant Relapse in Chronic Lymphocytic Leukemia. Leukemia, 27, 1659-1665. https://doi.org/10.1038/leu.2013.52
Martinez-Lopez, J., Narasimhan, B., et al. (2014) Prognostic Value of Deep Sequencing Method for Minimal Residual Disease Detection in Multiple Mieloma. Blood, 123, 3073-3079. https://doi.org/10.1182/blood-2014-01-550020
Mancuso, P., Calleri, A., Antoniotti, P., Quarna, J., Prumeri, G. and Bertolini, F. (2010) If It Is in the Marrow, Is It Also in the Blood? An Analysis of 1000 Paired Samples from Patients with B-Cell Non-Hodgkin Lymphoma. BMC Cancer, 10, 644. https://doi.org/10.1186/1471-2407-10-644
Kristensen, L.S., Hansen, J.W., Kristensen, S.S., Tholstrup, D., Harslof, L.B., Pedersen, O.B., De Nully Brown, P. and Gronbaek, K. (2016) Aberrant Methylation of Cell-Free Circulating DNA in Plasma Predicts Poor Outcome in Diffuse Large B Cell Lymphoma. Clinical Epigenetics, 8, 95. https://doi.org/10.1186/s13148-016-0261-y
Favier, O., Heutte, N., Stamatoullas-Bastard, A., Carde, P., Van’t Veer, M.B., Aleman, B.M., Noordijk, E.M., Thomas, J., Fermé, C. and Henry-Amar, M. (2009) European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Survival after Hodgkin Lymphoma: Causes of Death and Excess Mortality in Patients Treated in 8 Consecutive Trials. Cancer, 115, 1680-1691. https://doi.org/10.1002/cncr.24178
Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sivers, E.L. and Forero-Torres, A. (2010) Brentuximab Vedotin (SGN-35) for Relapsed CD30Positive Lymphomas. The New England Journal of Medicine, 363, 1812-1821. https://doi.org/10.1056/NEJMoa1002965
Minich, S.S. (2012) Brentuximab Vedotin: A New Age in the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma. Annals of Pharmacotherapy, 46, 377-383. https://doi.org/10.1345/aph.1Q680
Camus, V., Stamatoullas, A., Mareschal, S., Viailly, P.J., Srafan-Vasseur, N., Bohers, E., Dubois, S., Picquenot, J.M., Ruminy, P., Maingonnat, C., Bertrand, P., Comic, M., Tallon-Simon, V., Becker, S., Veresezan, L., Frebour, T., Vera, P., Bastard, P., Tilly, H. and Jardin, F. (2016) Detection and Prognostic Value of Recurrent Exportin 1 Mutations in Tumor and Cell-Free Circulating DNA of Patients with Classical Hodgkin Lymphoma. Haematologica, 101, 1094-1101. https://doi.org/10.3324/haematol.2016.145102
Jones, K., Nourse, J.P., Keane, C., Bhatnagar, A. and Gandhi, M.K. (2013) Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma. Predictive Biomarkers and Personalized Medicine, 20, 253-264.
Van Eijndhoven, M.A.J., Zijlstra, J.M., Groenewegen, N.J., Drees, E.E.E., van Niele, S., Rubina Baglio, D., van der Voorn, H., Libregts, S.F.W.M., Wauben, M.H.M., de Menezes, R.X., van Weering, J.R.T., Nieuwland, R., Visser, L., van den Berg, A., de Jong, D. and Michiel Pegtel, D. (2016) Plasma Vesicle miRNAs for Therapy Response Monitoring in Hodgkin Lymphoma Patients. JCI Insight, 1, e89631. https://doi.org/10.1172/jci.insight.89631
Primerano, S., Burnelli, R., Carraro, E., Pillon, M., Elia, C., Farruggia, P., Sala, A., Vinti, L., Buffardi, S., Basso, G., Mascarin, M. and Mussolin, L. (2016) Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma. Journal of Cancer, 7, 364-366. https://doi.org/10.7150/jca.13593
Calvano, A., La Rocca, F., Simeon, V., Girasole, M., Dinarelli, S., Laurenzana, I., De Stradis, A., De Luca, L., Trino, S., Traficante, A., D’Arena, G., Mansueto, G., Villani, O., Pietrantuono, G., Laurenti, L., Del Vecchio, L. and Musto, P. (2017) MicroRNA-155 in Serum-Derived Extracellular Vesicles as a Potential Biomarker for Hematological Malignancies—A Short Report. Cellular Oncology, 40, 97-103. https://doi.org/10.1007/s13402-016-0300-x
Vasioukhin, V., Anker, P., Maurice, P., Lyautey, J., Lederrey, C. and Stroun, M. (1994) Point Mutations of the N-Ras Gene in the Blood Plasma of Patients with Myelodisplastic Síndrome Ora Cute Myelogenous Leukaemia. British Journal of Haematology, 86, 774-779. https://doi.org/10.1111/j.1365-2141.1994.tb04828.x
Koutova, L., Sterbova, M., Pazourkova, E., Pospisilova, S., Svobodova, I., Horinek, A., Lysak, D. and Korabecna, M. (2015) The Impact of Standard Chemotherapy on miRNA Signature in Plasma in AML Patients. Leukemia Research, 39, 1389-1395. https://doi.org/10.1016/j.leukres.2015.08.009
Mithraprabhu, S., Khong, T., Ramachandran, M., Chow, A., Klarica, D., Mai, L., Walsh, S., Broemeling, D., Marziali, A., Wiggin, A., Hocking, J., Kalff, A., Durie, B. and Spencer, A. (2017) Circulating Tumour DNA Analysis Demonstrates Spatial Mutational Heterogeneity That Coincides with Disease Relapse in Myeloma. Leukemia, Epub ahead of print. https://doi.org/10.1038/leu.2016.366
Oberle, A., Brandt, A., Voigtiaender, M., Thiele, B., Radioff, J., Schulenkorf, A., Alawi, M., Marz, M., Ford, C.T., Krohn-Grimberghe, A. and Binder, M. (2017) Monitoring Multiple Myeloma by Next-Generatin Sequencing of V(D)J Rearrangements from Circulating Myeloma Cells and Cell-Free Myeloma DNA. Hematologica, Epub ahead of print. https://doi.org/10.3324/haematol.2016.161414
Isin, M., Ozqur, E., Cetin, G., Erten, N., Aktan, M., Gezer, U. and Dalay, N. (2014) Investigation of Circulating lncRNAs in B-Cell Neoplasms. Clinica Chimica Acta, 431, 255-259.